– Reaffirms commitment to quality, excellence

As part of efforts to strengthen partnerships and drive business growth, Ranbaxy Nigeria Limited (a Sun Pharma company) has recognised no fewer than 40 distributors across the country for their outstanding performance in 2025.
The recognition took place at the company’s annual partners’ reward forum, where top-performing distributors were honoured with awards across various categories in acknowledgement of their contributions to the company’s distribution network and market expansion.
Among the leading awardees were Softland Pharmaceutical, Onitsha; Kuka Medicals, Kano; Ogbuagu Pharmaceutical Company Limited; and Dimatts Pharma, Onitsha, alongside several others who distinguished themselves in sales performance and market reach during the year under review.
The awards, presented in the form of plaques, were handed to the top category of winners by Ranbaxy’s Regional Head, Mr Indranil Sen, who commended the distributors for their dedication and resilience in a competitive pharmaceutical market.
Also speaking at the event, the company’s Country Head (Sales and Marketing), Dr Ekwe Onyeaboh, said the initiative was in fulfilment of Ranbaxy’s promise to reward excellence among its partners.
He noted that the company had, at the beginning of 2025, pledged to recognise distributors who met or exceeded their sales targets, adding that the awards demonstrate the company’s commitment to integrity and quality in its operations.
According to him, “Ranbaxy is known for integrity and quality, and this recognition is part of our effort to appreciate those who have aligned with our values and delivered exceptional results.”
Onyeaboh further highlighted the company’s global footprint, describing it as a reputable international pharmaceutical firm with extensive human and infrastructural capacity.
“Sun Pharma is a global company with over 2,000 world-class scientists and more than 45 manufacturing facilities worldwide. It has a workforce of over 43,000 people drawn from more than 50 nationalities, reflecting its global presence and diversity,” he said.
He added that the company operates as a vertically integrated organisation with a strong presence in multiple markets, enabling it to maintain high standards in production and distribution.
Focusing on Nigeria, Onyeaboh reiterated the company’s commitment to local manufacturing, noting that Ranbaxy operates a factory in Magboro, Ogun State. He encouraged distributors to take advantage of opportunities to visit the facility and gain first-hand insight into the company’s production processes and quality assurance standards.
“In Nigeria, we have our factory in Magboro, and I encourage our partners to visit and see what Ranbaxy has put in place. This will further strengthen your confidence in our products and operations,” he said.
Beyond recognising past performance, the forum also provided an avenue for the company to outline its strategic direction for 2026, particularly in areas relating to sales, credit and operational policies.
Onyeaboh explained that the company would continue to refine its sales and credit frameworks, as well as its secondary implementation, economic and financial policies, to ensure better alignment with market realities and to support distributors in achieving greater success.
He emphasised that clear policy guidelines would not only enhance transparency in business dealings but also enable distributors to better understand the company’s expectations and opportunities for growth.





